Further evidence for the interaction of μ- and δ-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S): A spinal c-Fos protein study in the rat under carrageenin inflammation

Brain Research

Volumn 967, Issue 1-2, 2003, Pages 106-112

  Le Guen, Stéphanie ^b   Catheline, Gwénaëlle ^a   Fournié Zaluski, Marie Claude ^b   Roques, Bernard Pierre ^b   Besson, Jean Marie ^a   Buritova, Jaroslava ^a  

^a PSL RESEARCH UNIVERSITY   (France)

^b Laboratoire de Pharmacochimie   (France)

Author keywords

c Fos protein; Carrageenin inflammation; Endogenous enkephalin; Opioid receptor; RB101(S); Spinal cord

Indexed keywords

CARRAGEENAN; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; OPIATE RECEPTOR; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOREACTIVITY; INFLAMMATION; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT;

EID: 0345269158     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)04231-2     Document Type: Article

References (57)

1. Abbadie C., Honoré P., Fournié-Zaluski M.-C., Roques B.P., Besson J.-M. Effects of opioids and non-opioids on c-Fos immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation. Eur. J. Pharmacol. 258:1994;215-227.
2. Akil H., Owens C., Gutstein H.B., Taylor L., Curran E., Watson S. Endogenous opioids: overview and current issues. Drug Alcohol Depend. 51:1998;127-140.
3. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7:1984;309-338.
4. Besson J.-M., Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol. Rev. 67:1987;67-186.
5. Budai D., Fields H.L. Endogenous opioid peptides acting at mu-opioid receptors in the dorsal horn contribute to midbrain modulation of spinal nociceptive neurons. J. Neurophysiol. 79:1998;677-687.
6. Buritova J., Honoré P., Chapman V., Besson J.-M. Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and spinal c-Fos expression in the rat: synergistic mechanisms. Pain. 64:1996;559-568.
7. Carlton S.M., Coggeshall R.E. Immunohistochemical localization of enkephalin in peripheral sensory axons in the rat. Neurosci. Lett. 221:1997;121-124.
8. G. Catheline, S. Le Guen, F. Noble, M.-C. Fournié-Zaluski, B.P. Roques, J.-M. Besson, J. Buritova, Which types of opioid receptors are involved in the antinociceptive effects of RB101(S)?, Abstract, INRC, Seattle, USA, 2000.
9. Catheline G., Le Guen S., Besson J.-M. Effects of opioid receptor antagonists on the effects of i.v. morphine on carrageenin evoked c-Fos expression in the superficial dorsal horn of the rat spinal cord. Brain Res. 824:1999;105-111.
10. Chapman V., Besson J.-M. Pharmacological studies of nociceptive systems using the c-fos immunohistochemical technique: an indicator of noxiously activated spinal neurones. Dickenson A.H., Besson J.-M. Handbook of Experimental Pharmacology: The Pharmacology of Pain. 1997;235-279 Springer, Berlin.
11. Coggeshall R.E., Carlton S.M. Receptor localization in the mammalian dorsal horn and primary afferent neurons. Brain Res. Rev. 24:1997;28-66.
12. Coggeshall R.E., Zhou S., Carlton S.M. Opioid receptors on peripheral sensory axons. Brain Res. 764:1997;126-132.
13. Desmeules J.A., Kayser V., Guilbaud G. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 53:1993;277-285.
14. Desmeules J.A., Kayser V., Gacel G., Guilbaud G., Roques B.P. The highly selective delta agonist BUBU induces an analgesic effect in normal and arthritic rat and this action is not affected by repeated administration of low doses of morphine. Brain Res. 611:1993;243-248.
15. Dickenson A.H., Sullivan A.F., Roques B.P. Evidence that endogenous enkephalins and a delta opioid receptor agonist have a common site of action in spinal antinociception. Eur. J. Pharmacol. 148:1988;437-439.
16. Emmerson P.J., Liu M.R., Woods J.H., Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271:1994;1630-1637.
17. Fournié-Zaluski M.-C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., Roques B.P. 'Mixed inhibitor-prodrug' as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J. Med. Chem. 35:1992;2473-2481.
18. Fraser G.L., Pradhan A.A., Clarke P.B.S., Wahlestedt C. Supraspinal antinociceptive response to [D-Pen(2,5)]-enkephalin (DPDPE) is pharmacologically distinct from that to other delta-agonists in the rat. J. Pharmacol. Exp. Ther. 295:2000;1135-1141.
19. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J. Neurosci. 20:2000;U22-U26.
20. Harris J.A. Using c-fos as a neural marker of pain. Brain Res. Bull. 45:1998;1-8.
21. Hassan A.H.S., Ableitner A., Stein C., Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in inflamed tissue. Neuroscience. 55:1993;185-195.
22. Honoré P., Buritova J., Besson J.-M. Carrageenin-evoked c-Fos expression in rat lumbar spinal cord: the effects of indomethacin. Eur. J. Pharmacol. 272:1995;249-259.
23. Honoré P., Buritova J., Besson J.-M. The effects of morphine on carrageenin-induced spinal c-Fos expression are completely blocked by β-funaltrexamine, a selective mu opioid receptor antagonist. Brain Res. 732:1996;242-246.
24. B receptor antagonist as revealed by noxiously-evoked spinal c-Fos expression in the rat. J. Pharmacol. Exp. Ther. 281:1997;208-217.
25. Hurley R.W., Hammond D.L. Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal mu opioid receptor agonists after inflammatory injury. J. Neurosci. 21:2001;2536-2545.
26. Jordan B.A., Cvejic S., Devi L.A. Opioids and their complicated receptor complexes. Neuropsychopharmacology. 23:2000;S5-S18.
27. Le Guen S., Catheline G., Besson J.-M. Development of tolerance to the antinociceptive effect of systemic morphine at the lumbar spinal cord level: a c-Fos study in the rat. Brain Res. 813:1998;128-138.
28. Le Guen S., Honoré P., Catheline G., Fournié-Zaluski M.-C., Roques B.P., Besson J.-M. The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist. Brain Res. 834:1999;200-206.
29. Le Guen S., Noble F., Fournié-Zaluski M.-C., Roques B.P., Besson J.-M., Buritova J. Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA antagonist: a c-Fos study in a model of inflammatory nociception in rats. Third Congress of Pain in Europe-EFIC, PS1/053, Nice, France, 2000. 2000;207. abstract.
30. Levac B.A., O'Dowd B.F., George S.R. Oligomerization of opioid receptors: generation of novel signaling units. Curr. Opin. Pharmacol. 2:2002;76-81.
31. Maldonado R., Valverde O., Turcaud S., Fournié-Zaluski M.-C., Roques B.P. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation. Pain. 58:1994;77-83.
32. Maldonado R., Severini C., Matthes H.W., Kieffer B.L., Melchiorri P., Negri L. Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene. Br. J. Pharmacol. 132:2001;1485-1492.
33. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18:1995;22-29.
34. Matthes H.W., Smadja C., Valverde O., Vonesch J.L., Foutz A.S., Boudinot E., Denavit-Saubié M., Severini C., Negri L., Roques B.P., Maldonado R., Kieffer B.L. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J. Neurosci. 18:1998;7285-7295.
35. Morin-Surun M.P., Boudinot E., Dubois C., Matthes H.W., Kieffer B.L., Denavit-Saubié M., Champagnat J., Foutz A.S. Respiratory function in adult mice lacking the mu-opioid receptor: role of delta-receptors. Eur. J. Neurosci. 13:2001;1703-1710.
36. Noble F., Roques B.P. Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphine. Neurosci. Lett. 185:1995;75-78.
37. Noble F., Soleilhac J.M., Sorocas-Lucas E., Turcaud S., Fournié-Zaluski M.-C., Roques B.P. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261:1992;181-190.
38. Noble F., Smadja C., Roques B.P. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists. J. Pharmacol. Exp. Ther. 271:1994;1127-1134.
39. B receptor antagonist potentiates μ-, but not δ-opioid receptor-mediated antinociception in the formalin test. Eur. J. Pharmacol. 273:1995;145-151.
40. Noble F., Fournié-Zaluski M.-C., Roques B.P. Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity. Neuroscience. 75:1996;917-926.
41. Noble F., Fournié-Zaluski M.-C., Roques B.P. Future medication in the management of pain: complete inhibitors of enkephalin catabolism. Thérapie. 54:1999;121-133.
42. Ossipov M.H., Kovelowski C.J., Porreca F. The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw inflammation is blocked by naltrindole, a selective delta-opioid antagonist. Neurosci. Lett. 184:1995;173-176.
43. Ossipov M.H., Kovelowski C.J., Wheeler-Aceto H., Cowan A., Hunter J.C., Lai J., Malan T.P., Porreca F. Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone. J. Pharmacol. Exp. Ther. 277:1996;784-788.
44. Rexed B. The cytoarchitectonic organization of the spinal cord in the cat. J. Comp. Neurol. 96:1952;415-495.
45. Roques B.P., Noble F., Daugé V., Fournié-Zaluski M.-C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45:1993;87-146.
46. Rothman R.B., Long J.B., Bykov V., Jacobson A.E., Rice K.C., Holaday J.W. β-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J. Pharmacol. Exp. Ther. 247:1988;405-416.
47. Schmidt B.L., Tambeli C.H., Levine J.D., Gear R.W. Mu/delta cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat. Eur. J. Neurosci. 15:2002;861-868.
48. 125I]β-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex. J. Pharmacol. Exp. Ther. 253:1990;410-419.
49. Stein C., Gramsch C., Herz A. Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and β-endorphin. J. Neurosci. 10:1990;1292-1298.
50. Sullivan A.F., Dickenson A.H., Roques B.P. Delta-opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones. Br. J. Pharmacol. 98:1989;1039-1049.
51. Takemori A.E., Portoghese P.S. Selective naltrexone-derived opioid receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 32:1992;239-269.
52. Terenius L. The endogenous opioids and other central peptides. Wall P.D., Melzack R. Textbook of Pain. 1984;133-141 Churchill Livingstone, Edinburgh.
53. Traynor J.R., Elliott J. Delta-opioid receptor subtypes and cross-talk with mu-receptors. Trends Pharmacol. Sci. 14:1993;84-86.
54. Ward S.J., Portoghese P.S., Takemori A.E. Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J. Pharmacol. Exp. Ther. 220:1982;494-498.
55. Wu H., Hung K., Ohsawa M., Mizoguchi H., Tseng L.F. Antisera against endogenous opioids increase the nocifensive response to formalin: demonstration of inhibitory beta-endorphinergic control. Eur. J. Pharmacol. 421:2001;39-43.
56. Zimmerman D.M., Leander J.D., Reel J.K., Hynes M.D. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J. Pharmacol. Exp. Ther. 241:1987;374-378.
57. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.